Colorado Dangerous Drugs & Medical Devices

Fosamax®

Burg Simpson is not currently pursuing new Fosamax® cases.

Millions of Americans are prescribed Fosamax to help improve their bone density and fight osteoporosis. However, evidence suggests that Fosamax and its generic equivalent (alendronate), may actually be doing more harm than good and may be the cause of unusual and painful low-energy fractures of the femur (thigh bone).

FOSAMAX LINKED TO ATYPICAL FEMUR FRACTURES

Originally approved in 1995, Fosamax® is manufactured by Merck & Co, Inc. and belongs to a family of drugs know as bisphosphonates. Bisphosphonates are routinely prescribed to post-menopausal women and other individuals who are known to be at a high-risk of bone density deterioration.

In 2008, the results of an observational study, published in the Journal of Orthopedic Trauma, linked Fosamax® to a distinct type of fracture in the femur. The study of some 70 patients experiencing low-energy femur fractures (which occur when someone falls from a standing height or less) revealed that these patients all suffered a similar and distinct straight-line fracture of their femur. Furthermore, of the patients studied, more than a third had been taking Fosamax® for an average of five years or more.

PROLONGED USE OF FOSAMAX® MAY PUT WOMEN AT HIGHER RISK

Since the findings of that 2008 study, it would appear that orthopedic surgeons and bone specialists are continuing to see more and more of these unusual fractures among long-term users of Fosamax®, particularly in women. In February 2011, the results of a Canadian study, published in the online edition of the Journal of the American Medical Association suggested that women who had been on bisphosphonates such as Fosamax® for more than five years, had nearly three times higher risk of these unusual fractures than those with only transient exposure to the drugs.

FOSAMAX® AND OSTEONECROSIS OF THE JAW (ONJ; DEAD JAW)

In addition to causing potential femur fractures, prolonged use of Fosamax® and other bisphosphonates have long been linked to a rare condition that involves the loss, or breakdown, of the jaw bone called osteonecrosis of the jaw (ONJ) or dead jaw. In early 2005 the FDA requested that Merck and all other bisphosphonate manufacturers revise the Fosamax warning label to include a warning that their drugs may be related to the onset of ONJ. Osteonecrosis appears to occur when the bone tissue of the jaw fails to heal properly from any trauma that causes the jawbone to be exposed in the mouth. For example, this type of exposure can occur from something as simply as a tooth extraction. Once the jawbone begins to die, treatment generally focuses on eradicating infection and relieving pain. More aggressive treatments may include removing large portions of dead bone. The development of Osteonecrosis is associated with the use of Fosamax or other bisphosphonates.

Subsequent studies now suggested that Fosamax and other bisphoshonates might also lead to a breakdown and deterioration of bone tissue in the knee shoulder joints.

FLORIDA WOMAN AWARDED $8 MILLION FOR FOSAMAX® INJURIES

In 2010, a NYC jury awarded a Fosamax® user $8 million, finding that Fosamax® caused her ONJ. The case is In re Fosamax Products Liability Litigation, U.S. District Court, Southern District of New York (Manhattan), No. 06-1789.

FDA SAFETY WARNINGS

At the present time, FDA has not seen fit to issue a nationwide recall of Fosamax® or any of its generic equivalents and the drugs still remains commercially available. However, the FDA has issued numerous other warnings and consumer safety communications regarding bisphosphonates.

Fosamax® is a registered trademark of Merck & Co., Inc.

 

trophies

 February 13, 2020

Burg Simpson E-News: February 2020

Join Our Email List Complex Business and Commercial Litigation, Construction Defects, Dangerous Drugs & Medical Devices, Mass Tort, Class Action, Medical Malpractice, Personal Injury, and Workers’ Compensation FEBRUARY 2020 E-NEWS GOOD LAWYERS 5280 Magazine Recognizes Denver’s Top Lawyers for 2020 Burg Simpson Eldredge Hersh & Jardine is pleased to announce that Michael S. Burg , Peter W…. Read more »

 February 13, 2020

National Trial Lawyers Announces Top Lawyers for 2020!

National Trial Lawyers Announces the Top Lawyers for 2020! Burg Simpson is pleased to announce that the National Trial Lawyers Association has selected the Top 100 Attorneys and the Top 40 Under 40 Attorneys for 2020! The National Trial Lawyers Association is an invitation-only organization composed of the premier trial lawyers from each state or region… Read more »

 February 12, 2020

Mediation vs. Arbitration: Resolving Your Commercial Dispute

Mediation vs. Arbitration: Resolving Your Commercial Dispute Most commercial contracts have a provision stating that the parties will mediate disputes before taking the issue to arbitration or trial.  For those seeking to resolve a commercial dispute, it is important to know that litigation is typically expensive, time-consuming, public, and unpredictable. A trial’s outcome is always uncertain… Read more »

 February 11, 2020

Short-Term Healthcare Insurance & the Institutionalization of Post-Claims Underwriting

Jessica L. Derakhshanian and Shane C. Fulton, trial lawyers with Burg Simpson Eldredge Hersh & Jardine, recently published an article in the January edition of The Colorado Lawyer entitled Short-Term Healthcare Insurance and the Institutionalization of Post-Claims Underwriting. The article provides a review of short-term health insurance regulation over the last decade and analyzes the… Read more »

david-hersh-case-settlement

 December 9, 2019

Settling Commercial Litigation Cases

An out-of-court settlement is a legally-binding agreement between the parties to a lawsuit that effectively puts an end to the legal matter. A settlement resolves all disputes inherent in the lawsuit, and results in dismissal of the claims filed in court.  Sometimes a settlement will contain a requirement that other court orders be entered effectuating… Read more »

Holding Pharmaceutical Companies Responsible – Mass Tort | Dangerous Drugs & Medical Devices

 November 12, 2019

Holding Pharmaceutical Companies Responsible – Mass Tort | Dangerous Drugs & Medical Devices

Burg Simpson’s Colorado mass tort attorneys have represented thousands of people who have suffered serious side effects after taking dangerous medications or those who have been hurt by a defective product.  If you have suffered injuries related to a defective drug or medical device, contact the Burg Simpson mass tort team at 303-790-2525.

bike-crash-safety

 November 8, 2019

Bike Crash Safety Video – Burg Simpson Personal Injury

The personal injury attorneys at Burg Simpson help fellow bicycle enthusiasts understand how to protect their rights after a bike crash and stay safe on the roads. If you have been hurt in a bike crash and need help, reach out to us today by calling our office or filling out our online free case… Read more »

7th Annual Jeremy Bitner Memorial Run for the Fallen Officers Fund

 July 1, 2019

7th Annual Jeremy Bitner Memorial Run for the Fallen Officers Fund

The Jeremy Bitner Foundation was established in honor of Englewood Police Detective Jeremy Bitner. Detective Bitner lost his life in the line of duty on May 28, 2012, after being struck and killed by a vehicle while performing a traffic stop. Jeremy served the Englewood Police Department for 8 years and during that time was assigned… Read more »

Top 100 National Trial Lawyers Legal 500 Best Lawyers in America Super Lawyers US News 2014 Top 25 Most Influential Lawyers